

SITC 32nd Annual Meeting Clinical Trials in Progress Abstract Guidelines

Clinical Trials in Progress Abstract Overview & Criteria:

The Society for Immunotherapy of Cancer understands the crucial need for collaboration and discussion surrounding clinical trials in progress. This abstract submission category aims to allow for open dialogue surrounding such trials and hopes to foster a unique environment in which to discuss the research that is being done.

All phases of clinical research may be considered for inclusion in the Clinical Trials in Progress abstract submission. Although there are no absolute criteria for abstracts submitted under this category, we provide the following general guidelines for your consideration as you prepare your abstract submission for this category.

All abstracts submitted under this category, as for all abstracts in any category, are subject to peer review and possible rejection from being included as an oral and/or poster presentation in the 32nd Annual Meeting.

Submission Guidelines:

Background:

- Scientific background/rationale for the trial should be included
- Preclinical and/or earlier-phase clinical data that has already been publically presented or published may be included with references.
- Abstracts should be written/designed with respect to the correlates and hypothesis being tested in the clinical trial

Methods:

- Clinical trial registry number (required, if appropriate)
- Trial design and statistical methods (include)
- Treatment or intervention planned (include)
- Major eligibility criteria, highlighting unusual aspects (include)
- ***It is not a requirement that the trial be recruiting (current status of "Open but Not Yet Recruiting" is acceptable)***

NOT acceptable in a Trials in Progress abstract:

- Completed trials (these should be submitted in other categories)
- Brand or proprietary drug names